Antihyperglycemics (GLP-1 receptor agonists)
- Potent glucose lowering + weight loss
- Major role with obesity/ASCVD
- Semaglutide/liraglutide/dulaglutide
- Orforglipron = oral small-molecule agonist
- Nausea/vomiting common; titrate slowly
- Little hypoglycemia unless insulin/SU
- Slow gastric emptying affects some patients
- Early reports: lithium toxicity possible
Class at a glance
- Potent glucose lowering + weight loss
Members / distinctions
- Semaglutide/liraglutide/dulaglutide
- Little hypoglycemia unless insulin/SU
Pharmacology
- Orforglipron = oral small-molecule agonist
Clinical role
- Major role with obesity/ASCVD
- Nausea/vomiting common; titrate slowly
- Slow gastric emptying affects some patients
Safety / monitoring
- Early reports: lithium toxicity possible
Self-check
- What common GI adverse effects occur with GLP-1 agonists?
Nausea and vomiting. - What lithium-related concern has been reported with GLP-1 agonists?
Possible lithium toxicity.
Drugs in this class (6)
Antihyperglycemics (GLP-1 receptor agonists) prescription history
Animated chart of estimated U.S. prescriptions per year, Diabetes meds (1923–2026). GLP-1 agonist highlighted from 2005.
All drug classes · Open Antihyperglycemics (GLP-1 receptor agonists) in the interactive console ↗